Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
7.60
+0.74 (10.79%)
Aug 13, 2025, 4:00 PM - Market closed
Enanta Pharmaceuticals Revenue
Enanta Pharmaceuticals had revenue of $18.31M in the quarter ending June 30, 2025, with 1.91% growth. This brings the company's revenue in the last twelve months to $64.81M, down -9.94% year-over-year. In the fiscal year ending September 30, 2024, Enanta Pharmaceuticals had annual revenue of $67.64M, down -14.61%.
Revenue (ttm)
$64.81M
Revenue Growth
-9.94%
P/S Ratio
2.49
Revenue / Employee
$494,702
Employees
131
Market Cap
162.03M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 67.64M | -11.57M | -14.61% |
Sep 30, 2023 | 79.20M | -6.96M | -8.07% |
Sep 30, 2022 | 86.16M | -10.91M | -11.24% |
Sep 30, 2021 | 97.07M | -25.40M | -20.74% |
Sep 30, 2020 | 122.47M | -82.72M | -40.31% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ENTA News
- 2 days ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 - Business Wire
- 9 days ago - Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series - Business Wire
- 4 weeks ago - Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series - Business Wire
- 2 months ago - Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Business Wire
- 2 months ago - Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - Business Wire
- 3 months ago - Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting - Business Wire
- 3 months ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 - Business Wire
- 4 months ago - Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire